BioAtla
BCAB
87 hedge funds and large institutions have $96.1M invested in BioAtla in 2023 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 28 increasing their positions, 13 reducing their positions, and 19 closing their positions.
115% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 13
90% more call options, than puts
Call options by funds: $55K | Put options by funds: $29K
42% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 19
10% more funds holding
Funds holding: 79 → 87 (+8)
10% more capital invested
Capital invested by funds: $87.6M → $96.1M (+$8.51M)
0.03% less ownership
Funds ownership: 1.37% → 1.34% (-0.03%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.62M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.99M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$1.68M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.57M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$9.3M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$3.86M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$1.61M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.31M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$979K |
BCAB Hedge Fund Activity: Q2 2023 in Review
87 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in BioAtla (BCAB) for Q2 2023, worth a combined $96.1M — up 9.7% from $87.6M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new BCAB positions and 19 closed out — a net gain of 8 holders — while 28 added to existing stakes and 13 trimmed.
The largest buyer was BlackRock, adding an estimated $7.62M. The largest seller was OrbiMed, cutting an estimated $9.3M.
- 87 institutional investors held BioAtla (BCAB) as of Q2 2023, up from 79 in Q1 2023.
- Funds reported $96.1M of BioAtla stock for Q2 2023, up 9.7% quarter-over-quarter.
- 27 funds opened new BioAtla positions in Q2 2023 and 19 closed out, a net change of +8 holders.
- The largest BioAtla buyer in Q2 2023 was BlackRock, an estimated $7.62M added.
- The largest BioAtla seller in Q2 2023 was OrbiMed, an estimated $9.3M sold.
Based on aggregated 13F filings for Q2 2023.